Frequent office visits for injections may reduce adalimumab survival rate in patients with psoriasis

Chika OhataDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, JapanCorrespondence[email protected]

Takako ShintaniDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Masataka ArakawaDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Kazuhiro YoshimuraDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Bungo OhyamaDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Norito IshiiDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Fumitake OnoDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Takahiro HamadaDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Tadashi KarashimaDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

Minao FurumuraDepartment of Dermatology, Kurume University School of Medicine, Fukuoka, Japan

show all

References

Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with Psoriasis vulgaris. Br J Dermatol. 2011;164:1091–6
PubMed Web of Science ®Google Scholar
Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169:666–72
PubMed Web of Science ®Google Scholar
Lopez-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169:1141–7
PubMed Web of Science ®Google Scholar
Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008–13
PubMed Web of Science ®Google Scholar
van den Reek JM, van Lumig PP, Driessen RJ, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol. 2014;170:415–24
PubMed Web of Science ®Google Scholar
Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10:301–7
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Frequent office visits for injections may reduce adalimumab survival rate in patients with psoriasis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Frequent office visits for injections may reduce adalimumab survival rate in patients with psoriasis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date